Name: MRKR: Marker Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas
Creator: Stocktwits

SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Investors are fueling speculation around SpaceX as interest intensifies regarding the broader space economy and potential competitive positioning against other major tech players.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is seeing volatile trading as investors digest strong quarterly results and raised guidance, while some community members weigh the stock's significant recent gains against high valuation expectations. The conversation is currently split between those frustrated by the post-earnings pullback and bullish long-term investors pointing to the company's accelerating data center growth and AI infrastructure potential.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

Investors are closely monitoring SLV as silver retests historic support levels following significant volatility linked to shifting Middle East geopolitical tensions and persistent inflation. While the community debates whether the metal has found a definitive bottom, market participants are split between those accumulating physical silver as a long-term hedge against fiat debasement and those wary of the industrial demand cooling or further short-term downside.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include Core, Cognitive Adjacencies, and Network Software and Services. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks is rallying after management clarified supply chain guidance at a recent investor conference, helping to dispel post-earnings skepticism and renewing focus on record operating cash flows. The community is actively discussing the stock's potential for a breakout to new highs as hyperscaler demand for AI networking infrastructure continues to drive strong growth.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is currently in the spotlight as investors anticipate the company's next earnings report, with community sentiment heavily focused on its track record of beating estimates and potential for a significant re-rating. Much of the discourse centers on the stock's recent volatility and a new $1 billion credit facility, which has sparked speculation about future M&A activity and long-term scaling opportunities.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is seeing heavy community discussion and bullish sentiment following strong Q2 revenue growth that exceeded expectations and a guidance raise. Investors are closely monitoring the company's ability to scale manufacturing and secure new contracts as a potential catalyst to squeeze short positions and drive the stock toward prior highs.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is under heavy selling pressure as investors react to a failed phase 3 trial for ziltivekimab, raising broader concerns about the company's ability to innovate beyond its core GLP-1 business. While the company maintains its long-term financial guidance, the community is actively debating whether this decline represents a buying opportunity for a global market leader or a sign of deeper pipeline stagnation compared to competitors.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Walt Disney Co. is trending as investors weigh the stock's long-term valuation against its recent price consolidation and upcoming fiscal third-quarter earnings report. Community discussion is polarized, with some traders anticipating a bullish breakout driven by strong box office performance and streaming growth, while others express frustration over the stock's sluggish historical performance and ongoing debates regarding corporate strategy and leadership.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing heightened investor interest driven by strong Phase 3 clinical data, institutional accumulation, and ongoing speculation regarding potential strategic partnerships or a buyout. Community sentiment is largely bullish, with active discussions focused on the company's progress toward a BLA filing and its potential to address significant unmet needs in oncology.

Cameco Corp. engages in the provision of uranium. It operates through the Uranium and Fuel Services segments. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Cameco Corp is trending as investors weigh potential production disruptions in its Canadian mines alongside increased nuclear demand from the AI data center boom. The community remains divided between long-term investors holding for a multi-year uranium supply cycle and traders reacting to heightened volatility fueled by energy sector geopolitics.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker 

Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.


5 Small Drug Stocks to Invest in Amid a Biotech Comeback

Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.

MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?

MARKER THERAPEUTICS (MRKR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates

PROKIDNEY CP (PROK) delivered earnings and revenue surprises of -7.69% and +222.86%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

BioStem Technologies, Inc. (BSEM) Reports Q1 Loss, Tops Revenue Estimates

BioStem Technologies, Inc. (BSEM) delivered earnings and revenue surprises of -85.71% and +7.64%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates

MARKER THERAPEUTICS (MRKR) delivered earnings and revenue surprises of +80.49% and +83.83%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Profound Medical (PROF) Reports Q4 Loss, Misses Revenue Estimates

Profound Medical (PROF) delivered earnings and revenue surprises of 0.00% and -21.87%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know

Marker Therapeutics' shares jump 114% in three months as early MT-601 data showed strong responses, advanced into dose expansion, and lifted investor confidence.

Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics

Soleno Therapeutics leads a rebound in small drug stocks as innovation, pipeline progress and M&A activity fuel optimism for 2026.

MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?

Is it a good or bad thing when a stock experiences a golden cross technical event?

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.

Marker Therapeutics Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

MRKRMarker Therapeutics Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest MRKR News